Cargando…

Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension

BACKGROUND: Theoretically, angiotensin II receptor blockers (ARBs) have certain advantages over angiotensin-converting enzyme inhibitors, but the contribution of these advantages to the clinical effect of ARBs is not known. OBJECTIVE: To compare the efficacy and tolerability of telmisartan with enal...

Descripción completa

Detalles Bibliográficos
Autores principales: Akat, Pramod B., Bapat, Tushar R., Murthy, Mangala B., Karande, Vitthal B., Burute, Shreyas R.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937316/
https://www.ncbi.nlm.nih.gov/pubmed/20871766
http://dx.doi.org/10.4103/0253-7613.66838
_version_ 1782186558491721728
author Akat, Pramod B.
Bapat, Tushar R.
Murthy, Mangala B.
Karande, Vitthal B.
Burute, Shreyas R.
author_facet Akat, Pramod B.
Bapat, Tushar R.
Murthy, Mangala B.
Karande, Vitthal B.
Burute, Shreyas R.
author_sort Akat, Pramod B.
collection PubMed
description BACKGROUND: Theoretically, angiotensin II receptor blockers (ARBs) have certain advantages over angiotensin-converting enzyme inhibitors, but the contribution of these advantages to the clinical effect of ARBs is not known. OBJECTIVE: To compare the efficacy and tolerability of telmisartan with enalapril in patients of essential hypertension. MATERIALS AND METHODS: Patients of mild to moderate hypertension were randomized to receive either 40 mg of telmisartan or enalapril 10 mg once a day orally for 12 weeks. At each visit, the systolic blood pressure (BP), diastolic BP and heart rate of each patient were recorded. Investigations such as hemogram hemoglobin, total leucocytes count (Hb, TLC), serum creatinine, serum glutamic oxaloacetic transaminase, serum glutamic pyruric transaminase (SGOT, SGPT) random blood sugar and urine examination were performed at baseline and after 12 weeks of the treatment period. RESULTS: The mean reduction in systolic BP in the telmisartan/enalapril group was 26.38 ± 10.98/26.74 ± 8.24 mmHg while the mean reduction in diastolic BP in the telmisartan/enalapril group was 14 ± 2.98/9.71 ± 4.23 mmHg, respectively, at 12 weeks. When the reduction in systolic BP in the two groups was compared, there was no significant difference between the groups (P > 0.05). However, the mean reduction in diastolic BP achieved with telmisartan at 12 weeks was significantly higher (P < 0.001) than that achieved with enalapril after the corresponding period. The overall frequency of adverse-effects was similar. However, in the enalapril group, the incidence of dry cough was higher as compared to that in the telmisartan group (11.43% vs. 0%, respectively; P < 0.05). CONCLUSION: Telmisartan produces a greater reduction in diastolic BP than enalapril and is free from the adverse-effect of dry cough that is commonly encountered with enalapril.
format Text
id pubmed-2937316
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-29373162010-09-24 Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension Akat, Pramod B. Bapat, Tushar R. Murthy, Mangala B. Karande, Vitthal B. Burute, Shreyas R. Indian J Pharmacol Research Article BACKGROUND: Theoretically, angiotensin II receptor blockers (ARBs) have certain advantages over angiotensin-converting enzyme inhibitors, but the contribution of these advantages to the clinical effect of ARBs is not known. OBJECTIVE: To compare the efficacy and tolerability of telmisartan with enalapril in patients of essential hypertension. MATERIALS AND METHODS: Patients of mild to moderate hypertension were randomized to receive either 40 mg of telmisartan or enalapril 10 mg once a day orally for 12 weeks. At each visit, the systolic blood pressure (BP), diastolic BP and heart rate of each patient were recorded. Investigations such as hemogram hemoglobin, total leucocytes count (Hb, TLC), serum creatinine, serum glutamic oxaloacetic transaminase, serum glutamic pyruric transaminase (SGOT, SGPT) random blood sugar and urine examination were performed at baseline and after 12 weeks of the treatment period. RESULTS: The mean reduction in systolic BP in the telmisartan/enalapril group was 26.38 ± 10.98/26.74 ± 8.24 mmHg while the mean reduction in diastolic BP in the telmisartan/enalapril group was 14 ± 2.98/9.71 ± 4.23 mmHg, respectively, at 12 weeks. When the reduction in systolic BP in the two groups was compared, there was no significant difference between the groups (P > 0.05). However, the mean reduction in diastolic BP achieved with telmisartan at 12 weeks was significantly higher (P < 0.001) than that achieved with enalapril after the corresponding period. The overall frequency of adverse-effects was similar. However, in the enalapril group, the incidence of dry cough was higher as compared to that in the telmisartan group (11.43% vs. 0%, respectively; P < 0.05). CONCLUSION: Telmisartan produces a greater reduction in diastolic BP than enalapril and is free from the adverse-effect of dry cough that is commonly encountered with enalapril. Medknow Publications 2010-06 /pmc/articles/PMC2937316/ /pubmed/20871766 http://dx.doi.org/10.4103/0253-7613.66838 Text en © Indian Journal of Pharmacology http://creativecommons.org/licenses/by/2.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Akat, Pramod B.
Bapat, Tushar R.
Murthy, Mangala B.
Karande, Vitthal B.
Burute, Shreyas R.
Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
title Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
title_full Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
title_fullStr Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
title_full_unstemmed Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
title_short Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
title_sort comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937316/
https://www.ncbi.nlm.nih.gov/pubmed/20871766
http://dx.doi.org/10.4103/0253-7613.66838
work_keys_str_mv AT akatpramodb comparisonoftheefficacyandtolerabilityoftelmisartanandenalaprilinpatientsofmildtomoderateessentialhypertension
AT bapattusharr comparisonoftheefficacyandtolerabilityoftelmisartanandenalaprilinpatientsofmildtomoderateessentialhypertension
AT murthymangalab comparisonoftheefficacyandtolerabilityoftelmisartanandenalaprilinpatientsofmildtomoderateessentialhypertension
AT karandevitthalb comparisonoftheefficacyandtolerabilityoftelmisartanandenalaprilinpatientsofmildtomoderateessentialhypertension
AT buruteshreyasr comparisonoftheefficacyandtolerabilityoftelmisartanandenalaprilinpatientsofmildtomoderateessentialhypertension